Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insomnia is associated with increased risk for suicide. The Food and Drug Administration (FDA) has mandated that warnings regarding suicide be included in the prescribing information for hypnotic medications. The authors conducted a review of the evidence for and against the claim that hypnotics increase the risk of suicide. METHOD: This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiazepines, limiting its findings to adults. PubMed and Web of Science were searched, crossing the terms "suicide" and "suicidal" with each of the modern FDA-approved hypnotics. The FDA web site was searched for postmarketing safety reviews, and the FDA was contacted with requests to provide detailed case reports for hypnotic-related suicide deaths reported through its Adverse Event Reporting System. RESULTS: Epidemiological studies show that hypnotics are associated with an increased risk for suicide. However, none of these studies adequately controlled for depression or other psychiatric disorders that may be linked with insomnia. Suicide deaths have been reported from single-agent hypnotic overdoses. A separate concern is that benzodiazepine receptor agonist hypnotics can cause parasomnias, which in rare cases may lead to suicidal ideation or suicidal behavior in persons who were not known to be suicidal. On the other hand, ongoing research is testing whether treatment of insomnia may reduce suicidality in adults with depression. CONCLUSIONS: The review findings indicate that hypnotic medications are associated with suicidal ideation. Future studies should be designed to assess whether increases in suicidality result from CNS impairments from a given hypnotic medication or whether such medication decreases suicidality because of improvements in insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This confirms previous findings, suggesting increasing levels of suicidal ideation, suicide attempts, and suicide risk in patients administered with Z-drugs (Brower et al., 2011; MCCall et al., 2017).”
From An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions (2019) · cites this paper as MCCall et al., 2017
In the citing paper
“The impact of benzodiazepines on the risk of suicidal behaviours is unknown.8”
From Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Watson, W. A., Litovitz, T. L., Rodgers, G. C., Klein-Schwartz, W., Reid, N., Youniss, J., Flanagan, A., & Wruk, K. M. (2005) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.05.001 · Cited by 1,148
Edinger, J. D., Bonnet, M. H., Bootzin, R. R., Doghramji, K., Dorsey, C. M., Espie, C. A., Jamieson, A. O., McCall, W. V., Morin, C. M., & Stepanski, E. J. (2004) · Sleep · doi:10.1093/sleep/27.8.1567 · Cited by 1,039
Self-citationMowry, J. B., Spyker, D. A., Cantilena, L. R., McMillan, N., & Ford, M. (2014) · Clinical Toxicology · doi:10.3109/15563650.2014.987397 · Cited by 849
Ancoli‐Israel, S., & Roth, T. G. (1999) · PubMed · Cited by 776
Insomnia and daytime cognitive performance: A meta-analysis
Fortier-Brochu, É., Beaulieu-Bonneau, S., Ivers, H., & Morin, C. M. (2012) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2011.03.008 · Cited by 753 · cited 2×
“Cognitive impairment, specifically problems with decision making and executive function, are common to both insomnia and suicide;(44;45) hence further cognitive impairment at the time of peak drug effect may further tilt the balance towards suicide.”
BackgroundBronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2009) · Clinical Toxicology · doi:10.3109/15563650903438566 · Cited by 485
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Self-citationBronstein, A. C., Spyker, D. A., Cantilena, L. R., Rumack, B. H., & Dart, R. C. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.746424 · Cited by 421
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.543906 · Cited by 354
National Use of Prescription Medications for Insomnia: NHANES 1999-2010
Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014) · Sleep · doi:10.5665/sleep.3410 · Cited by 305 · cited 1×
“The latter possibility has public health significance as 3% of non-institutionalized adult Americans reported using a hypnotic in the last month.(6) Up to 10% of adults in the USA use over the counter sleep aids,(7) but over the counter sleep aids have not been linked with suicide, carry no FDA warnings for suicide, a…”
BackgroundProblem-solving in suicide attempters
POLLOCK, L. R., & WILLIAMS, J. M. G. (2004) · Psychological Medicine · doi:10.1017/s0033291703008092 · Cited by 242 · cited 2×
“Cognitive impairment, specifically problems with decision making and executive function, are common to both insomnia and suicide;(44;45) hence further cognitive impairment at the time of peak drug effect may further tilt the balance towards suicide.”
BackgroundInsomnia severity is an indicator of suicidal ideation during a depression clinical trial
McCall, W. V., Blocker, J. N., D’Agostino, R., Kimball, J., Boggs, N., Lasater, B., & Rosenquist, P. B. (2010) · Sleep Medicine · doi:10.1016/j.sleep.2010.04.004 · Cited by 236 · cited 1×
“(3)The relationship between insomnia and suicide is maintained after controlling for symptoms of depressive illness.(4) It is not clear whether insomnia is causally related to suicide, or is an indicator for some other factor that drives the risk for suicide, such as Central Nervous System and psychological hyperarous…”
BackgroundSelf-citationThe Link Between Suicide and Insomnia: Theoretical Mechanisms
McCall, W. V., & Black, C. G. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0389-9 · Cited by 219 · cited 4×
“This review aims to describe: (1) the toxicology of hypnotics in the setting of suicide; (2) the epidemiologic relationship between hypnotic use and suicide; and (3) illustrative case data on hypnotics and suicide as found in the published literature and FDA databases that have generally not been included in published…”
BackgroundInfluentialSelf-citationMortality Hazard Associated with Prescription Hypnotics
Kripke, D. F., Klauber, M. R., Wingard, D. L., Fell, R. L., Assmus, J. D., & Garfinkel, L. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00292-8 · Cited by 184 · cited 1×
“The American Cancer Society evaluated frequency of “prescription sleeping pills” use in a convenience sample of 1,099,830 participants in 1982.(18) Respondents selfdetermined whether they were taking a “prescription sleeping pill” and hence the data likely mixed benzodiazepines with barbiturates and antidepressants.”
BackgroundChronic hypnotic use: deadly risks, doubtful benefit
Kripke, D. F. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.1999.0076 · Cited by 147
Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010.
Kaufmann, C. N., Spira, A. P., Alexander, G. C., Rutkow, L., & Mojtabai, R. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3951 · Cited by 105 · cited 2×
“While the available data might give the impression that some hypnotics are more likely to be associated with suicide than others, this conclusion should be tempered by the large variation in the time that different agents have been available and the different rates of prescribing.(43)”
BackgroundResultIs usage of hypnotics associated with mortality?
Mallon, L., Broman, J., & Hetta, J. E. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.12.004 · Cited by 101 · cited 2×
“Data were collected regarding sleeping problems, medical diagnoses, depression, and body mass index.(21) McCall et al.”
BackgroundMethodMcCall, W. V., Blocker, J. N., D’Agostino, R., Kimball, J. N., Boggs, N., Lasater, B., Haskett, R. F., Krystal, A. D., McDonald, W. M., & Rosenquist, P. B. (2010) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27872 · Cited by 99 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundSelf-citationRisk of suicide attempts after benzodiazepine and/or antidepressant use
Neutel, C. I., & Patten, S. B. (1997) · Annals of Epidemiology · doi:10.1016/s1047-2797(97)00126-9 · Cited by 88
Brower, K. J., McCammon, R. J., Wojnar, M., Ilgen, M. A., Wojnar, J., & Valenstein, M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05484gry · Cited by 83 · cited 1×
“to a question inquiring about the use of sleeping pills such as Ambien or Sonata in the last 12 months.(15) Of these, 2.”
BackgroundAssociation Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study
Sun, Y., Lin, C.-C., Lu, C.-J., Hsu, C. Y., & Kao, C. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.10.022 · Cited by 74 · cited 1×
“Each suicide case was matched on age, gender, occupation, and urban vs rural setting with 10 controls without history of suicide attempts.(17) The adjusted odds ratio for exposure to zolpidem was 2.”
MethodThe role of benzodiazepines in elderly suicides
Carlsten, A., Waern, M., Holmgren, P., & Allebeck, P. (2003) · Scandinavian Journal of Public Health · doi:10.1080/14034940210167966 · Cited by 70 · cited 1×
“(14) Upon reviewing all suicides in Sweden between 1992–1996, the authors found that after correcting for the differences in rates of prescribing for the hypnotics flunitrazepam, nitrazepam, zopiclone, and zolpidem, the associations between these 4 hypnotics and suicide were about the same, with approximately 1 suicid…”
BackgroundYoussef, N. A., & Rich, C. L. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802177698 · Cited by 68
Sedatives and suicide: the San Diego study
Mendelson, W. B., & Rich, C. L. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03469.x · Cited by 64 · cited 1×
“7% of cases, and a third of those taking hypnotics also tested positive for alcohol.(12) There were no cases in which a benzodiazepine was the only drug detected and also judged to be the sole cause of death.”
BackgroundBEN-HAMOU, M., MARSHALL, N. S., GRUNSTEIN, R. R., SAINI, B., & FOIS, R. A. (2011) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2011.00919.x · Cited by 51 · cited 2×
“”(37) They calculated an odds ratio of 8.”
BackgroundAcute Zolpidem Overdose--Report of Two Cases
Gock, S. B., Wong, S. H., Nuwayhid, N., Venuti, S. E., Kelley, P. D., Teggatz, J. R., & Jentzen, J. M. (1999) · Journal of Analytical Toxicology · doi:10.1093/jat/23.6.559 · Cited by 48 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundJonas, J. M., & Hearron, A. E. J. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606000-00003 · Cited by 45 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundToxicology and Characteristics of Deaths Involving Zolpidem in New South Wales, Australia 2001–2010*
Darke, S. G., Deady, M., & Duflou, J. A. (2012) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2012.02117.x · Cited by 35 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundAllgulander, C., & Näsman, P. (1991) · Psychosomatic Medicine · doi:10.1097/00006842-199101000-00009 · Cited by 34 · cited 3×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundWinek, C. L., Wahba, W. W., Janssen, J. K., Rozin, L., & Rafizadeh, V. (1996) · Forensic Science International · doi:10.1016/0379-0738(95)01875-1 · Cited by 32 · cited 1×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundTriazolam Blood Concentrations in Forensic Cases in Canada*
Joynt, B. P. (1993) · Journal of Analytical Toxicology · doi:10.1093/jat/17.3.171 · Cited by 32 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundLichtenwalner, M., & Tully, R. (1997) · Journal of Analytical Toxicology · doi:10.1093/jat/21.7.567 · Cited by 31 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundMethodEffect of psychopharmacotherapy on suicide risk in psychiatric inpatients
Taiminen, T. J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03328.x · Cited by 27 · cited 1×
“A retrospective case-control study examined medications prescribed to 25 Finnish psychiatric inpatients who died by suicide during their hospitalization compared with 25 inpatient controls matched on age, gender, and psychiatric diagnosis (schizophrenia [n=14]; major depression [n=7]; personality disorder [n=3]; ‘neur…”
MethodSuicide with Psychotropic Drugs in Switzerland
Michel, K., Arestegui, G., & Spühler, T. (1994) · Pharmacopsychiatry · doi:10.1055/s-2007-1014289 · Cited by 22 · cited 1×
“(13) However, the authors conceded that the role of alcohol in these ‘single-agent’ cases may have been underestimated.”
BackgroundMcEntire, D., Kirkpatrick, D. R., Kerfeld, M. J., Hambsch, Z. J., Reisbig, M. D., Agrawal, D. K., & Youngblood, C. F. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.966815 · Cited by 22
McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., Hodges, C., Gubosh, B., McCloud, L., Newman, J. C., Case, D., Rumble, M. E., et al. (2015) · Clinical Trials · doi:10.1177/1740774515573958 · Cited by 21 · cited 1×
“(5) In the meantime, the proposition of routinely prescribing hypnotics to suicidal depressed patients is countered by the fact that hypnotics can be part of an intentional overdose, or may induce or aggravate suicide.”
BackgroundSelf-citationDistribution of Triazolam and α-Hydroxytriazolam in a Fatal Intoxication Case*†
LEVINE, B. S., Grieshaber, A., Pestaner, J. P., Moore, K. A., & Smialek, J. E. (2002) · Journal of Analytical Toxicology · doi:10.1093/jat/26.1.52 · Cited by 21
Zolpidem-induced suicide attempt: a case report
Hejri, S. M., Faizi, M., & Babaeian, M. (2013) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-21-77 · Cited by 21 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundA case of fatal triazolam overdose
Moriya, F., & Hashimoto, Y. (2003) · Legal Medicine · doi:10.1016/s1344-6223(02)00074-3 · Cited by 18 · cited 3×
“• A 57 year old man was found dead outdoors in winter in Japan.”
BackgroundAderjan, R., & Mattern, R. (1979) · Archives of Toxicology · doi:10.1007/bf00695876 · Cited by 17 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundAssociation of sedative–hypnotic medications with suicidality
Pae, C., Koh, J. S., Lee, S.-J., Han, C., Patkar, A. A., & Masand, P. S. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.9 · Cited by 15
McIntyre, I. M., Syrjanen, M. L., Lawrence, K., DOW, C. A., & Drummer, O. H. (1994) · Journal of Forensic Sciences · doi:10.1520/jfs13746j · Cited by 13 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundAcute Flurazepam Intoxication: A Case Report
Martello, S., Oliva, A., De‐Giorgio, F., & Chiarotti, M. (2006) · American Journal of Forensic Medicine & Pathology · doi:10.1097/01.paf.0000201106.59902.fb · Cited by 9
Eszopiclone ingestions reported to Texas poison control centers, 2005—2006
Forrester, M. B. (2007) · Human & Experimental Toxicology · doi:10.1177/0960327107084045 · Cited by 7 · cited 2×
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
Background
Research works printed but not linked: 1
- Mary Ross Southwork - Division of Drug Risk Evaluation ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides D050402 D050403 D050404. 8-31-2006 Center for Drug Evaluation and Research of the Food and Drug Administration
Cited by
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial
McCall, W. V., Benca, R. M., Rosenquist, P. B., Youssef, N. A., McCloud, L., Newman, J. C., Case, D., Rumble, M. E., Szabo, S. T., Phillips, M., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030267 · Cited by 157
Self-citationKearns, J. C., Coppersmith, D. D. L., Santee, A. C., Insel, C., Pigeon, W. R., & Glenn, C. R. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.09.011 · Cited by 115
Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit
Kripke, D. F. (2016) · F1000Research · doi:10.12688/f1000research.8729.1 · Cited by 106
Palagini, L., Manni, R., Aguglia, E., Amore, M., Brugnoli, R., Bioulac, S., Bourgin, P., Micoulaud‐Franchi, J., Girardi, P., Grassi, L. G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.688890 · Cited by 107
“In psychiatric disorders, either one of these two actions and their combination could have interesting effects in clinical practice (10, 11).”
Background
Metadata
- Authors
- McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., McCloud, L., Newman, J. C., Case, D., Rumble, M., & Krystal, A. D.
- Affiliations
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-01-01
- Volume
- 174
- Issue
- 1
- Pages
- 18-25
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5205566
- OpenAlex
- W2510989636
- Cited by
- 139
- References
- 44
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 12 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 21 · 2019: 14 · 2018: 29 · 2017: 6
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH095778, R01MH095776, R01MH095780)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- hypnotics, suicide risk, insomnia, benzodiazepines, benzodiazepine receptor agonists, suicidal ideation, parasomnias, depression, FDA warning, post-marketing safety, adverse event reporting
- MeSH terms
- Suicide Prevention, Adult, Aged, Cause of Death, Dose-Response Relationship, Drug, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Middle Aged, Product Surveillance, Postmarketing, Prospective Studies, Risk, Suicide, United States, United States Food and Drug Administration, Cohort Studies, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.